Wasatch Advisors’s Aquestive Therapeutics AQST Stock Holding History

Wasatch Advisors’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3M	Sell	648,173 -737,670	-53%	-$3.28M	0.02%	199
2026 Q2	$5.77M	Buy	1,385,843 +507,527	+58%	+$2.14M	0.04%	170
2026 Q1	$3.65M	Buy	878,316 +197,076	+29%	+$800K	0.02%	180
2025 Q4	$4.4M	Sell	681,240 -43,038	-6%	-$268K	0.03%	180
2025 Q3	$4.05M	Buy	+724,278	New	+$3.13M	0.02%	196
2019 Q1	–	Sell	-145,373	Closed	-$916K	–	224
2018 Q4	$916K	Hold	145,373	–	–	0.01%	223
2018 Q3	$2.54M	Buy	+145,373	New	+$2.4M	0.03%	215

Other funds holding AQST

Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Pavaki Capital Management Pueblo, Colorado $294M AUM 34.46% 1-Year Est. Return

Sugar Maple Asset Management Sister Bay, Wisconsin $175M AUM 16.33% 1-Year Est. Return

Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return

Penbrook Management New York $169M AUM 32.52% 1-Year Est. Return

Trust Point Inc La Crosse, Wisconsin $1.33B AUM 20.56% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.68B AUM 22.33% 1-Year Est. Return

ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

Wasatch Advisors's AQST Position: Q3 2026 in Review

Wasatch Advisors reduced its Aquestive Therapeutics (AQST) stake by 53% in Q3 2026, selling an estimated $3.28M and leaving 648,173 shares worth $3M. The position accounts for 0.02% of the portfolio, ranked #199.

Wasatch Advisors first reported a position in AQST in Q3 2018 and has held it in 7 quarters since. The position peaked at $5.77M in Q2 2026. 35 funds tracked by Wall St. Rank hold AQST as of Q3 2026.

Wasatch Advisors held 648,173 shares of Aquestive Therapeutics worth $3M as of Q3 2026.
Wasatch Advisors sold 737,670 Aquestive Therapeutics shares in Q3 2026, an estimated $3.28M.
Aquestive Therapeutics made up 0.02% of Wasatch Advisors's portfolio in Q3 2026, its #199 holding.
Wasatch Advisors first reported a position in Aquestive Therapeutics in Q3 2018 and has held it in 7 quarters since.
Wasatch Advisors's Aquestive Therapeutics position peaked at $5.77M in Q2 2026.
35 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2026.

Based on Wasatch Advisors's 13F filing for Q3 2026, filed 13 Oct 2026.